2021 Fiscal Year Final Research Report
To investigate the exosomal microRNA within portal blood for the aim of individualization of the multimodal therapy for pancreatic cancer
| Project/Area Number |
20K17669
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 55020:Digestive surgery-related
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2020-04-01 – 2022-03-31
|
| Keywords | 膵癌 / 集学的治療 / バイオマーカー / subclinical tumor |
|---|
| Outline of Final Research Achievements |
Pancreatic ductal adenocarcinoma (PDAC) is a critical disease with a poor prognosis because of high recurrence rate after curative resection. Multidisciplinary treatments including adjuvant chemotherapy (AC) significantly improved prognosis of patients with PDAC. However, there is no useful biomarker to manage the administration of AC. It is awaiting the optimal biomarker which can indicate not only the presence of subclinical tumor but also the tumor concerning chemo-sensitivity. We have conducted a comprehensive investigation of microRNA (miR) expression in various patient blood after surgery for PDAC to identify candidate miR which would be an optimal indicator for AC. We detected miR-26a-5p as a crucial candidate indicating the patients who were sensitive to AC. In this study, we evaluated whether the candidate gene expression in blood after surgery could distinguish the patients who were sensitive to AC.
|
| Free Research Field |
消化器外科
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究では画像診断でとらえられない膵癌のsubclinical腫瘍に対する治療効果モニタリングに有用な診断ツールを開発することで，最適な治療を過不足なく行える，個別化した膵癌集学的治療の確立を最終目標としている．
本研究では，subclinical腫瘍に対する治療である術後補助化学療法について着目し，その治療効果をモニタリングできる可能性のある候補遺伝子バイオマーカーを同定し，発表した．この結果は膵癌集学的治療をより効果的に運用できる可能性がある．
|
